Results 11 to 20 of about 33,680 (119)

Targeted Extracellular Vesicle Gene Therapy for Modulating Alpha-Synuclein Expression in Gut and Spinal Cord

Pharmaceutics, 2023
The development of effective disease-modifying therapies to halt Parkinson’s disease (PD) progression is required. In a subtype of PD patients, alpha-synuclein pathology may start in the enteric nervous system (ENS) or autonomic peripheral nervous system.
Maria Izco, Martin Schleef, Marco Schmeer, Estefania Carlos, Guglielmo Verona, Lydia Alvarez-Erviti   +5 more
doaj   +1 more source

Alpha-synuclein levels in blood plasma decline with healthy aging. [PDF]

PLoS ONE, 2015
There is unequivocal evidence that alpha-synuclein plays a pivotal pathophysiological role in neurodegenerative diseases, and in particular in synucleinopathies.
Niklas K U Koehler, Elke Stransky, Mirjam Meyer, Susanne Gaertner, Mona Shing, Martina Schnaidt, Maria S Celej, Thomas M Jovin, Thomas Leyhe, Christoph Laske, Anil Batra, Gerhard Buchkremer, Andreas J Fallgatter, Dorothee Wernet, Elke Richartz-Salzburger   +14 more
doaj   +1 more source

The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein

Molecular Neurodegeneration, 2010
Background Parkinson's disease (PD) involves the selective damage of dopaminergic neuron cells resulting from the accumulation and fibril formation of alpha-synuclein.
Kobayashi Natsuki, Kobayashi Masaki, Harada Ryuichi, Kim Jihoon, Sode Koji   +4 more
doaj   +1 more source

Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation

Neurobiology of Disease, 2020
In Parkinson's disease, some of the first alpha-synuclein aggregates appear in the olfactory system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain regions.
Christopher Mezias, Nolwen Rey, Patrik Brundin, Ashish Raj   +3 more
doaj   +1 more source

High-Affinity Detection of Alpha-Synuclein by Aptamer-Gold Conjugates on an Amine-Modified Dielectric Surface

Journal of Analytical Methods in Chemistry, 2019
Parkinson’s disease (PD) is a progressive health issue and influences an increasingly larger number of people, especially at older ages, affecting the central nervous system (CNS).
Xuemei You, Subash C. B. Gopinath, Thangavel Lakshmipriya, Dingan Li   +3 more
doaj   +1 more source

Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson’s disease

Scientific Reports, 2023
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, but no disease modifying therapies have been successful in clinical translation presenting a major unmet medical need.
Danuta Sastre, Faria Zafar, C. Alejandra Morato Torres, Desiree Piper, Deniz Kirik, Laurie H. Sanders, L. Stanley Qi, Birgitt Schüle   +7 more
doaj   +1 more source

Deposits of disease-associated alpha-synuclein may be present in the dura mater in Lewy body disorders: implications for potential inadvertent transmission by surgery

Free Neuropathology, 2020
Deposition of alpha-synuclein in the brain is a hallmark of Lewy body disorders. Alpha-synuclein has been considered to show prion-like properties.
Ellen Gelpi, Naomi P. Visanji, Selma Hönigschnabl, Angelika Reiner, Peter Fischer, Anthony Lang, Herbert Budka, Gabor G. Kovacs   +7 more
doaj   +1 more source

Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson’s Disease Risk

Frontiers in Cellular Neuroscience, 2021
Alpha-synuclein accumulation in dopaminergic neurons is one of the primary features of Parkinson’s disease (PD). Despite its toxic properties during PD, alpha-synuclein has some important physiological functions.
Alix Booms, Gerhard A. Coetzee
doaj   +1 more source

Formation of toxic oligomeric alpha-synuclein species in living cells.

PLoS ONE, 2008
BackgroundMisfolding, oligomerization, and fibrillization of alpha-synuclein are thought to be central events in the onset and progression of Parkinson's disease (PD) and related disorders.
Tiago Fleming Outeiro, Preeti Putcha, Julie E Tetzlaff, Robert Spoelgen, Mirjam Koker, Filipe Carvalho, Bradley T Hyman, Pamela J McLean   +7 more
doaj   +1 more source

Alpha synuclein and inflammaging

Heliyon
The α-synuclein protein is an established molecule in Lewy body pathology, especially Parkinson's disease (PD). While the pathological role of α-synuclein (α-syn) in PD has been well described, novel evidence may suggest that α-syn interacts with ...
Geneviève L. Putnam, Robert W. Maitta
doaj   +1 more source